To read the full story, subscribe or sign in.

DOV Shares Crushed After Phase III Bicifadine Failure

April 26, 2006

Poor Phase III data nearly halved DOV Pharmaceutical Inc.'s stock value Tuesday after the findings were unveiled late Monday. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

In 2025, science’s biggest story was political

BioWorld Science

In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...

Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

BioWorld Science

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...